Impact of CYP and ABCB1 Polymorphisms on Bortezomib-Induced Adverse Events in Multiple Myeloma
: Genetic variation in ABCB1 and CYP3A4, together with clinical factors such as TP53 mutation and sex, may contribute to interindividual variability in BTZ safety in MM. These findings should be considered exploratory given the sample size and require confirmation in larger cohorts. Nonetheless, they suggest a potential role for pharmacogenomics in supporting future approaches to treatment personalization.
Authors
- Noelia Pérez-Gómez (ORCID: https://orcid.org/0009-0007-4694-7469)
- Gonzalo Benzo
- María Victoria Cuevas (ORCID: https://orcid.org/0000-0001-7991-1234)
- Cristina Alonso-Madrigal
- Beatriz Cuevas (ORCID: https://orcid.org/0000-0001-7555-3361)
- Andrea Rodríguez-López (ORCID: https://orcid.org/0000-0003-4061-0439)
- Gerardo Hermida
- Miriam Sáiz-Rodríguez
- Rodolfo Álvarez-Nuño
- Antonio Sanz-Solas (ORCID: https://orcid.org/0000-0002-3305-692X)
- Raquel Alcaraz (ORCID: https://orcid.org/0000-0002-7501-5798)
- J. Labrador
- Natalia Busto (ORCID: https://orcid.org/0000-0001-9637-1209)
- Jesús Novalbos (ORCID: https://orcid.org/0000-0001-5384-4512)
- María González-Oter (ORCID: https://orcid.org/0009-0000-1887-4644)
- Natalia García-Sancha
- Raquel Vinuesa
- Francisco Abad-Santos
- Francisco Javier Díaz-Gálvez
Institutions
- Universidad de Valladolid (ES)
- Consejo Superior de Investigaciones Científicas (ES)
- Hospital Santiago Apostol (ES)
- Hospital Universitario de Burgos (ES)
- Hospital Universitario de La Princesa (ES)
- Instituto de Biomedicina y Genética Molecular de Valladolid (ES)
- Universidad de Burgos (ES)
- Universidad Autónoma de Madrid (ES)
Publication Details
- Journal
- Biomedicines
- Published
- 2026-04-01
- DOI
- https://doi.org/10.3390/biomedicines14040805
- Primary Topic
- Multiple Myeloma Research and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Ministerio de Ciencia e Innovación
- Instituto de Salud Carlos III